Legal & General Group’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $523K | Sell |
34,969
-2,875
| -8% | -$43K | ﹤0.01% | 2431 |
|
|
2025
Q1 | $611K | Buy |
37,844
+354
| +0.9% | +$5.71K | ﹤0.01% | 2339 |
|
|
2024
Q4 | $873K | Buy |
37,490
+8,335
| +29% | +$194K | ﹤0.01% | 2287 |
|
|
2024
Q3 | $857K | Buy |
29,155
+5,892
| +25% | +$173K | ﹤0.01% | 2288 |
|
|
2024
Q2 | $547K | Buy |
23,263
+6,231
| +37% | +$146K | ﹤0.01% | 2392 |
|
|
2024
Q1 | $646K | Buy |
+17,032
| New | +$646K | ﹤0.01% | 2335 |
|
|
2022
Q3 | – | Sell |
-131
| Closed | -$2K | – | 3488 |
|
|
2022
Q2 | $2K | Hold |
131
| – | – | ﹤0.01% | 3490 |
|
|
2022
Q1 | $8K | Hold |
131
| – | – | ﹤0.01% | 3453 |
|
|
2021
Q4 | $16K | Hold |
131
| – | – | ﹤0.01% | 3350 |
|
|
2021
Q3 | $26K | Hold |
131
| – | – | ﹤0.01% | 3185 |
|
|
2021
Q2 | $23K | Sell |
131
-60
| -31% | -$10.5K | ﹤0.01% | 3249 |
|
|
2021
Q1 | $38K | Sell |
191
-4
| -2% | -$796 | ﹤0.01% | 2913 |
|
|
2020
Q4 | $38K | Hold |
195
| – | – | ﹤0.01% | 2878 |
|
|
2020
Q3 | $35K | Sell |
195
-72
| -27% | -$12.9K | ﹤0.01% | 2801 |
|
|
2020
Q2 | $62K | Buy |
267
+124
| +87% | +$28.8K | ﹤0.01% | 2673 |
|
|
2020
Q1 | $17K | Sell |
143
-49
| -26% | -$5.83K | ﹤0.01% | 2972 |
|
|
2019
Q4 | $37K | Buy |
192
+6
| +3% | +$1.16K | ﹤0.01% | 2945 |
|
|
2019
Q3 | $36K | Hold |
186
| – | – | ﹤0.01% | 2883 |
|
|
2019
Q2 | $30K | Buy |
186
+50
| +37% | +$8.07K | ﹤0.01% | 3021 |
|
|
2019
Q1 | $27K | Buy |
136
+39
| +40% | +$7.74K | ﹤0.01% | 2981 |
|
|
2018
Q4 | $18K | Hold |
97
| – | – | ﹤0.01% | 3120 |
|
|
2018
Q3 | $23K | Hold |
97
| – | – | ﹤0.01% | 3152 |
|
|
2018
Q2 | $26K | Buy |
+97
| New | +$26K | ﹤0.01% | 3084 |
|